Q2 2018 13F Holders as of 30 Jun 2018
-
Type / Class
-
Debt / NOTE 2.250% 5/1
-
Market price (% of par)
-
144.57%
-
Total 13F principal
-
$472,971,000
-
Principal change
-
+$470,049,000
-
Total reported market value
-
$684,711,486
-
Number of holders
-
50
-
Value change
-
+$680,855,445
-
Number of buys
-
49
-
Number of sells
-
2
Institutional Holders of NEUROCRINE BIOSCIENCES INC - NOTE 2.250% 5/1 as of Q2 2018
As of 30 Jun 2018,
NEUROCRINE BIOSCIENCES INC - NOTE 2.250% 5/1 was held by
50 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$472,971,000
in principal (par value) of the bond.
The largest 10 bondholders included
Allianz Asset Management GmbH, FRANKLIN RESOURCES INC, Invesco Ltd., UBS ASSET MANAGEMENT AMERICAS INC, MACKAY SHIELDS LLC, LORD, ABBETT & CO. LLC, WELLS FARGO & COMPANY/MN, CALAMOS ADVISORS LLC, STATE STREET CORP, and DEUTSCHE BANK AG\.
This page lists
50
institutional bondholders reporting positions
for the Q2 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.